Ferrer Beginning Phase 3 Trial – Drug Discovery & Development

Ozenoxacin is a novel second generation non-fluorinated quinolone antibacterial agent undergoing clinical development, formulated as a topical one per cent cream, for infectious dermatological conditions. In preclinical studies, the bactericidal …